biostudies-literatureUnknownHsu CCTaipei Veterans General HospitalNational Science and Technology CouncilGilead Sciences<h4>Introduction</h4>Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are first-line nucleos(t)ide analogs (NA) for chronic hepatitis B (CHB). Real-world monitoring of patients on these agents and their comparative renal safety remain poorly characterized. We evaluated guideline-adherent monitoring practices and compared renal dysfunction risk across ETV, TDF, and TAF.<h4>Methods</h4>We retrospectively analyzed patients with CHB who initiated ETV, TDF, or TAF between 2012 and 2022. Levels of serum alanine aminotransferase, total bilirubin, albumin, serum creatinine, hepatitis B virus DNA, and abdominal sonograms were assessed every 6 months during the 36 months of NA treatment. Incidence rates and adjusted hazard ratios (HRs) for renal dysfunction were Clinical and translational gastroenterologyhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC12922928biostudies-literatureMonitoring Adherence and Renal Safety of Nucleos(t)ide Analogs for Patients With Chronic Hepatitis B.PMC12922928V111B-043, V111EA-017, V113C-141, V114C-234, V115C-246, Center of Excellence for Cancer Research MOHW112-TDU-B-221-124007, Y.L. Lin Hung Tai Education Foundation, and Big Data Center.CO-TW-988-6355MOST 111-2635-B-075-001, NSTC 112-2314-B-075-043-MY2Chou CYHsu CCChang YLChou YCWu JCSu CWChen ZEHou MCChao FHfalseMonitoring Adherence and Renal Safety of Nucleos(t)ide Analogs for Patients With Chronic Hepatitis B.<h4>Introduction</h4>Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are first-line nucleos(t)ide analogs (NA) for chronic hepatitis B (CHB). Real-world monitoring of patients on these agents and their comparative renal safety remain poorly characterized. We evaluated guideline-adherent monitoring practices and compared renal dysfunction risk across ETV, TDF, and TAF.<h4>Methods</h4>We retrospectively analyzed patients with CHB who initiated ETV, TDF, or TAF between 2012 and 2022. Levels of serum alanine aminotransferase, total bilirubin, albumin, serum creatinine, hepatitis B virus DNA, and abdominal sonograms were assessed every 6 months during the 36 months of NA treatment. Incidence rates and adjusted hazard ratios (HRs) for renal dysfunction were 2025-01-01T00:00:00Z2025 Dec2026-07-16T12:57:28.17Z2026-07-09T10:56:37.695ZS-EPMC129229284136372910.14309/ctg.0000000000000962